Holter and ambulatory ECG monitoring
Choosing between Holter, patch, event recorder, implantable loop recorder and smartwatch by symptom frequency, reading a Holter report line by line (pauses, AV block, ectopy burden, runs, symptom correlation), and the Medicare rules.
Tier 2Medical sciences concept
Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made
At a glance
- The question is always "what rhythm was present during the symptom?" A recording that captures the symptom, normal or abnormal, is the goal.
- Match the device to how often symptoms happen. A 24-hour Holter only suits daily symptoms.
- Read the report for pauses, AV block, ectopy burden, runs and symptom correlation, then decide whether it changes management.
Loading the rest of the note…
Finished reading?
Sources
- Medicare Benefits Schedule items 11716 (continuous ambulatory ECG 12 hours or more) and 11717 (patient-activated event recorder 7 to 30 days), with note DN.1.28AU/NZAustralian Government Department of Health, Disability and Ageing (MBS Online), accessed November 2026
- Medicare Benefits Schedule items 38285 (implantable loop recorder for unexplained syncope) and 38288 (implantable loop recorder after embolic stroke of undetermined source)AU/NZAustralian Government Department of Health, Disability and Ageing (MBS Online), accessed November 2026
- Brignole M, Moya A, de Lange FJ et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J 2018;39(21):1883-1948European Society of Cardiology, 2018
- Van Gelder IC, Rienstra M, Bunting KV et al. 2024 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2024;45:3314-414European Society of Cardiology, 2024
- Steinberg JS, Varma N, Cygankiewicz I et al. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Heart Rhythm 2017;14:e55-e96International Society for Holter and Noninvasive Electrocardiology and Heart Rhythm Society, 2017
- Recio-Ibarz MJ, Olóriz T, Calvo N et al. Premature ventricular complex-induced cardiomyopathy, a review: current insights, diagnostic challenges, and therapeutic strategies. J Clin Med 2026;15(4):1360 (summarises ESC 2022: ablation first-line, Class I, for symptomatic RVOT or fascicular PVCs)Journal of Clinical Medicine, 2026
- Healey JS, Lopes RD, Granger CB et al. Apixaban for stroke prevention in subclinical atrial fibrillation (ARTESIA). N Engl J Med 2024;390:107-17New England Journal of Medicine, 2024
- Last updated
- 14 November 2026
What changed
- 14 November 2026 Turnstile bot check on sign-in and signed-out feedback